+Follow
wslam
No personal profile
6
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
wslam
08-18
Good
wslam
08-18
Good
wslam
08-16
$美國中期國債 1.875% 2027/02/28(US91282CEC10.BOND)$
wslam
08-16
$騰訊控股(00700)$
wslam
08-16
$小米集團-W(01810)$
wslam
08-16
Good , win
wslam
10:14
Good
wslam
08-24 16:14
Good
@慕容風股評:GLP-1RA能否提前進入糖尿病治療路徑?
wslam
08-23
Good
wslam
08-22
Good
@段飛特:需求已經達到產能的150%,還在擔心科技見頂? 1、長債收益率一日遊,債券壓力依然存在昨晚
$美國30年期國債收益率(US30Y.BOND)$
重新收復週三貝森特出手的影響,此前打下去的收益率基本又漲回來了 只要你的財政紀律沒有實質性的約束,你的債務規模就是會不斷擴張的 美債的風險問題從零幾年的時候就開始討論了,現在已經20年過去了,哪屆ZF真的解決過這個問題?就算你想解決,你敢加稅嗎?你的選民答應嗎? 另外科技股的資本支出毫無放緩的意向,雖然長債收益率在攀升,但是並不影響他們的發債節奏,這點貝森特說的倒是真的,科技公司對債券利率真的沒那麼敏感 關於長債的收益率,昨晚貝森特還是再次強調了一下,戶部有強大的工具箱,下個月開始的國債收購規模可能超過40億美元的上限 但是光靠回購也只能影響短期走向,改變不了趨勢,要想長債收益率降低,我覺得指望財政紀律約束是有點難了,不如指望通脹降溫,聯儲局繼續減息吧 如果接下來通脹能夠降溫,長債收益率降低的話,對科技股來說就是宏觀順風,如果長債收益率持續快速的走高,對科技股來說終究是壓製作用 2、真的該重新審視存儲的邏輯了 昨天的文章講,這波長債收益率對科技股的衝擊其實是次要因素,是個導火索,其調整的核心邏輯還是反彈見頂,市場需要時間繼續盤整消化 從這兩天的盤面看市場主要也是內部切換,硬件和軟件蹺蹺板效應,並非邏輯破裂的崩潰式走勢 所以要想把握科技股的長期走勢,還是要看科技股自身的基本面情況,這裏不得不再次強調一下存儲板塊 很多人還是擔憂存儲是不是還是週期股,這波漲價見頂之後股價就要大幅回落了? 其實不然,之前已經多次和大家解讀過,這波存儲的週期屬性已經被大幅減弱了,即使不敢完全把它當成成長股來看,也要對這波週期上行
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4246837204037102","uuid":"4246837204037102","gmtCreate":1783736010063,"gmtModify":1786842518474,"name":"wslam","pinyin":"wslam","introduction":"","introductionEn":null,"signature":"","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":6,"tweetSize":15,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.08.12","exceedPercentage":"60.51%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.07.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":5,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":600774612177672,"gmtCreate":1787710474396,"gmtModify":1787710477126,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4246837204037102","idStr":"4246837204037102"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/600774612177672","isVote":1,"tweetType":1,"viewCount":25,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":600136286150960,"gmtCreate":1787559288758,"gmtModify":1787559291430,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4246837204037102","idStr":"4246837204037102"},"themes":[],"title":"","htmlText":"Good ","listText":"Good ","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/600136286150960","repostId":"599535294231744","repostType":1,"repost":{"id":599535294231744,"gmtCreate":1787412576386,"gmtModify":1787559010531,"author":{"id":"4141520327734232","authorId":"4141520327734232","name":"慕容風股評","avatar":"https://community-static.tradeup.com/news/63610cfc631c9f4a6adb40c67a289ee2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4141520327734232","idStr":"4141520327734232"},"themes":[],"title":"GLP-1RA能否提前進入糖尿病治療路徑?","htmlText":"過去治療2型糖尿病,常見做法是先控制飲食和運動,再使用二甲雙胍;血糖仍不達標,才逐級加入磺脲類、DPP-4抑制劑、SGLT2抑制劑或注射藥物,最後才考慮胰島素。這套模式成本較低、醫生經驗充足,卻容易把治療變成追逐糖化血紅蛋白數字:每次等待數月,待血糖失控才加藥,患者的體重、心血管及腎臟風險可能已持續累積。 GLP-1受體激動劑(GLP-1RA)的角色因而正在改變。問題已不是「是否比二甲雙胍更強」,而是哪一類患者若延後使用,可能錯過較佳的風險幹預窗口。 從逐級加藥走向風險分層 新版指南已不再要求所有患者依循同一條路徑。《中國糖尿病防治指南(2024版)》強調早期良好控制及合理聯合治療;對合併動脈粥樣硬化性心血管疾病或屬高危者,應選擇具有明確心血管獲益證據的GLP-1RA或SGLT2抑制劑;若患者超重或肥胖,用藥時亦應把減重效果列為重要考慮。美國糖尿病協會2026年標準更進一步,對已確診或高風險心血管疾病患者,建議使用具有結局證據的GLP-1RA,而不必等待糖化血紅蛋白失控,也不以是否已使用二甲雙胍為前提。 這不等於GLP-1RA應全面取代二甲雙胍。對沒有肥胖、心腎疾病而血糖升幅溫和的患者,二甲雙胍仍具價格低、經驗成熟及可及性高等優勢。若患者以心力衰竭或慢性腎病為主要風險,SGLT2抑制劑往往更具優先性;出現嚴重高血糖、酮症或明顯消瘦時,胰島素亦不能被延誤。 較適合提前使用GLP-1RA的,主要是肥胖、心血管高危、需要避免體重增加,或容易發生低血糖的患者。GLP-1RA以葡萄糖依賴方式促進胰島素分泌,單獨使用的低血糖風險較低,也避免部分磺脲類及胰島素帶來的體重增加。不過,胃腸道反應、注射接受程度、長期依從性及藥費,仍會令「指南推薦」與「真實使用」存在距離。 派達康要跨越的不只是獲批門檻 派格生物(02565.HK)的維培那肽注射液派達康,是觀察這場路徑轉變的合適案例。產品於20","listText":"過去治療2型糖尿病,常見做法是先控制飲食和運動,再使用二甲雙胍;血糖仍不達標,才逐級加入磺脲類、DPP-4抑制劑、SGLT2抑制劑或注射藥物,最後才考慮胰島素。這套模式成本較低、醫生經驗充足,卻容易把治療變成追逐糖化血紅蛋白數字:每次等待數月,待血糖失控才加藥,患者的體重、心血管及腎臟風險可能已持續累積。 GLP-1受體激動劑(GLP-1RA)的角色因而正在改變。問題已不是「是否比二甲雙胍更強」,而是哪一類患者若延後使用,可能錯過較佳的風險幹預窗口。 從逐級加藥走向風險分層 新版指南已不再要求所有患者依循同一條路徑。《中國糖尿病防治指南(2024版)》強調早期良好控制及合理聯合治療;對合併動脈粥樣硬化性心血管疾病或屬高危者,應選擇具有明確心血管獲益證據的GLP-1RA或SGLT2抑制劑;若患者超重或肥胖,用藥時亦應把減重效果列為重要考慮。美國糖尿病協會2026年標準更進一步,對已確診或高風險心血管疾病患者,建議使用具有結局證據的GLP-1RA,而不必等待糖化血紅蛋白失控,也不以是否已使用二甲雙胍為前提。 這不等於GLP-1RA應全面取代二甲雙胍。對沒有肥胖、心腎疾病而血糖升幅溫和的患者,二甲雙胍仍具價格低、經驗成熟及可及性高等優勢。若患者以心力衰竭或慢性腎病為主要風險,SGLT2抑制劑往往更具優先性;出現嚴重高血糖、酮症或明顯消瘦時,胰島素亦不能被延誤。 較適合提前使用GLP-1RA的,主要是肥胖、心血管高危、需要避免體重增加,或容易發生低血糖的患者。GLP-1RA以葡萄糖依賴方式促進胰島素分泌,單獨使用的低血糖風險較低,也避免部分磺脲類及胰島素帶來的體重增加。不過,胃腸道反應、注射接受程度、長期依從性及藥費,仍會令「指南推薦」與「真實使用」存在距離。 派達康要跨越的不只是獲批門檻 派格生物(02565.HK)的維培那肽注射液派達康,是觀察這場路徑轉變的合適案例。產品於20","text":"過去治療2型糖尿病,常見做法是先控制飲食和運動,再使用二甲雙胍;血糖仍不達標,才逐級加入磺脲類、DPP-4抑制劑、SGLT2抑制劑或注射藥物,最後才考慮胰島素。這套模式成本較低、醫生經驗充足,卻容易把治療變成追逐糖化血紅蛋白數字:每次等待數月,待血糖失控才加藥,患者的體重、心血管及腎臟風險可能已持續累積。 GLP-1受體激動劑(GLP-1RA)的角色因而正在改變。問題已不是「是否比二甲雙胍更強」,而是哪一類患者若延後使用,可能錯過較佳的風險幹預窗口。 從逐級加藥走向風險分層 新版指南已不再要求所有患者依循同一條路徑。《中國糖尿病防治指南(2024版)》強調早期良好控制及合理聯合治療;對合併動脈粥樣硬化性心血管疾病或屬高危者,應選擇具有明確心血管獲益證據的GLP-1RA或SGLT2抑制劑;若患者超重或肥胖,用藥時亦應把減重效果列為重要考慮。美國糖尿病協會2026年標準更進一步,對已確診或高風險心血管疾病患者,建議使用具有結局證據的GLP-1RA,而不必等待糖化血紅蛋白失控,也不以是否已使用二甲雙胍為前提。 這不等於GLP-1RA應全面取代二甲雙胍。對沒有肥胖、心腎疾病而血糖升幅溫和的患者,二甲雙胍仍具價格低、經驗成熟及可及性高等優勢。若患者以心力衰竭或慢性腎病為主要風險,SGLT2抑制劑往往更具優先性;出現嚴重高血糖、酮症或明顯消瘦時,胰島素亦不能被延誤。 較適合提前使用GLP-1RA的,主要是肥胖、心血管高危、需要避免體重增加,或容易發生低血糖的患者。GLP-1RA以葡萄糖依賴方式促進胰島素分泌,單獨使用的低血糖風險較低,也避免部分磺脲類及胰島素帶來的體重增加。不過,胃腸道反應、注射接受程度、長期依從性及藥費,仍會令「指南推薦」與「真實使用」存在距離。 派達康要跨越的不只是獲批門檻 派格生物(02565.HK)的維培那肽注射液派達康,是觀察這場路徑轉變的合適案例。產品於20","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/599535294231744","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":132,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":599739743027544,"gmtCreate":1787462480290,"gmtModify":1787462483006,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4246837204037102","idStr":"4246837204037102"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/599739743027544","isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":599195005837520,"gmtCreate":1787329570577,"gmtModify":1787329572002,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4246837204037102","idStr":"4246837204037102"},"themes":[],"title":"","htmlText":"Good ","listText":"Good ","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/599195005837520","repostId":"599035632738552","repostType":1,"repost":{"id":599035632738552,"gmtCreate":1787290664620,"gmtModify":1787321248345,"author":{"id":"4242190439147992","authorId":"4242190439147992","name":"段飛特","avatar":"https://community-static.tradeup.com/news/58c5dd517a3243d939006f06d2f74890","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4242190439147992","idStr":"4242190439147992"},"themes":[],"title":"","htmlText":"需求已經達到產能的150%,還在擔心科技見頂? 1、長債收益率一日遊,債券壓力依然存在昨晚 <a href=\"https://ttm.financial/S/US30Y.BOND\">$美國30年期國債收益率(US30Y.BOND)$ </a> 重新收復週三貝森特出手的影響,此前打下去的收益率基本又漲回來了 只要你的財政紀律沒有實質性的約束,你的債務規模就是會不斷擴張的 美債的風險問題從零幾年的時候就開始討論了,現在已經20年過去了,哪屆ZF真的解決過這個問題?就算你想解決,你敢加稅嗎?你的選民答應嗎? 另外科技股的資本支出毫無放緩的意向,雖然長債收益率在攀升,但是並不影響他們的發債節奏,這點貝森特說的倒是真的,科技公司對債券利率真的沒那麼敏感 關於長債的收益率,昨晚貝森特還是再次強調了一下,戶部有強大的工具箱,下個月開始的國債收購規模可能超過40億美元的上限 但是光靠回購也只能影響短期走向,改變不了趨勢,要想長債收益率降低,我覺得指望財政紀律約束是有點難了,不如指望通脹降溫,聯儲局繼續減息吧 如果接下來通脹能夠降溫,長債收益率降低的話,對科技股來說就是宏觀順風,如果長債收益率持續快速的走高,對科技股來說終究是壓製作用 2、真的該重新審視存儲的邏輯了 昨天的文章講,這波長債收益率對科技股的衝擊其實是次要因素,是個導火索,其調整的核心邏輯還是反彈見頂,市場需要時間繼續盤整消化 從這兩天的盤面看市場主要也是內部切換,硬件和軟件蹺蹺板效應,並非邏輯破裂的崩潰式走勢 所以要想把握科技股的長期走勢,還是要看科技股自身的基本面情況,這裏不得不再次強調一下存儲板塊 很多人還是擔憂存儲是不是還是週期股,這波漲價見頂之後股價就要大幅回落了? 其實不然,之前已經多次和大家解讀過,這波存儲的週期屬性已經被大幅減弱了,即使不敢完全把它當成成長股來看,也要對這波週期上行","listText":"需求已經達到產能的150%,還在擔心科技見頂? 1、長債收益率一日遊,債券壓力依然存在昨晚 <a href=\"https://ttm.financial/S/US30Y.BOND\">$美國30年期國債收益率(US30Y.BOND)$ </a> 重新收復週三貝森特出手的影響,此前打下去的收益率基本又漲回來了 只要你的財政紀律沒有實質性的約束,你的債務規模就是會不斷擴張的 美債的風險問題從零幾年的時候就開始討論了,現在已經20年過去了,哪屆ZF真的解決過這個問題?就算你想解決,你敢加稅嗎?你的選民答應嗎? 另外科技股的資本支出毫無放緩的意向,雖然長債收益率在攀升,但是並不影響他們的發債節奏,這點貝森特說的倒是真的,科技公司對債券利率真的沒那麼敏感 關於長債的收益率,昨晚貝森特還是再次強調了一下,戶部有強大的工具箱,下個月開始的國債收購規模可能超過40億美元的上限 但是光靠回購也只能影響短期走向,改變不了趨勢,要想長債收益率降低,我覺得指望財政紀律約束是有點難了,不如指望通脹降溫,聯儲局繼續減息吧 如果接下來通脹能夠降溫,長債收益率降低的話,對科技股來說就是宏觀順風,如果長債收益率持續快速的走高,對科技股來說終究是壓製作用 2、真的該重新審視存儲的邏輯了 昨天的文章講,這波長債收益率對科技股的衝擊其實是次要因素,是個導火索,其調整的核心邏輯還是反彈見頂,市場需要時間繼續盤整消化 從這兩天的盤面看市場主要也是內部切換,硬件和軟件蹺蹺板效應,並非邏輯破裂的崩潰式走勢 所以要想把握科技股的長期走勢,還是要看科技股自身的基本面情況,這裏不得不再次強調一下存儲板塊 很多人還是擔憂存儲是不是還是週期股,這波漲價見頂之後股價就要大幅回落了? 其實不然,之前已經多次和大家解讀過,這波存儲的週期屬性已經被大幅減弱了,即使不敢完全把它當成成長股來看,也要對這波週期上行","text":"需求已經達到產能的150%,還在擔心科技見頂? 1、長債收益率一日遊,債券壓力依然存在昨晚 $美國30年期國債收益率(US30Y.BOND)$ 重新收復週三貝森特出手的影響,此前打下去的收益率基本又漲回來了 只要你的財政紀律沒有實質性的約束,你的債務規模就是會不斷擴張的 美債的風險問題從零幾年的時候就開始討論了,現在已經20年過去了,哪屆ZF真的解決過這個問題?就算你想解決,你敢加稅嗎?你的選民答應嗎? 另外科技股的資本支出毫無放緩的意向,雖然長債收益率在攀升,但是並不影響他們的發債節奏,這點貝森特說的倒是真的,科技公司對債券利率真的沒那麼敏感 關於長債的收益率,昨晚貝森特還是再次強調了一下,戶部有強大的工具箱,下個月開始的國債收購規模可能超過40億美元的上限 但是光靠回購也只能影響短期走向,改變不了趨勢,要想長債收益率降低,我覺得指望財政紀律約束是有點難了,不如指望通脹降溫,聯儲局繼續減息吧 如果接下來通脹能夠降溫,長債收益率降低的話,對科技股來說就是宏觀順風,如果長債收益率持續快速的走高,對科技股來說終究是壓製作用 2、真的該重新審視存儲的邏輯了 昨天的文章講,這波長債收益率對科技股的衝擊其實是次要因素,是個導火索,其調整的核心邏輯還是反彈見頂,市場需要時間繼續盤整消化 從這兩天的盤面看市場主要也是內部切換,硬件和軟件蹺蹺板效應,並非邏輯破裂的崩潰式走勢 所以要想把握科技股的長期走勢,還是要看科技股自身的基本面情況,這裏不得不再次強調一下存儲板塊 很多人還是擔憂存儲是不是還是週期股,這波漲價見頂之後股價就要大幅回落了? 其實不然,之前已經多次和大家解讀過,這波存儲的週期屬性已經被大幅減弱了,即使不敢完全把它當成成長股來看,也要對這波週期上行","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/599035632738552","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":185,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":599040286868472,"gmtCreate":1787291818324,"gmtModify":1787291821152,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4246837204037102","idStr":"4246837204037102"},"themes":[],"title":"","htmlText":"Good ","listText":"Good ","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/599040286868472","repostId":"598995575214632","repostType":1,"repost":{"id":598995575214632,"gmtCreate":1787280802570,"gmtModify":1787280894373,"author":{"id":"4144466283079132","authorId":"4144466283079132","name":"沉穩","avatar":"https://community-static.tradeup.com/news/ceaf33910c228b133ddf5a00e3ddd318","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4144466283079132","idStr":"4144466283079132"},"themes":[],"title":"","htmlText":"蘋果(AAPL):從防禦壁壘轉身,開啟 AI 主線進攻 蘋果完全有潛力從「防禦型現金牛」轉型為「AI 主線進攻者」。 過去市場將蘋果視為避險港灣,主因其擁有龐大現金流與極低的 AI 資本支出(Capex)負擔;但隨著 Apple Intelligence 深度嵌入 iOS 生態系,它正掌握著全球最龐大的 AI 終端變現入口。 1. 資本輕量化優勢: 當其他科技巨頭陷入算力燒錢大戰、市場質疑 ROI 時,蘋果以輕資產架構實現 AI 落地,具備極高的獲利防禦力。 2. 超級換機潮與訂閱變現: 22 億獲利裝置的龐大基底,將推動由 AI 主導的 iPhone 超級換機週期,同時帶動高毛利的 Services(服務)訂閱營收加速增長。 短線的防禦屬性為其提供了極高的安全邊際,而終端 AI 的商業化爆發,正是驅動股價重新領漲美股的核心進攻引擎!","listText":"蘋果(AAPL):從防禦壁壘轉身,開啟 AI 主線進攻 蘋果完全有潛力從「防禦型現金牛」轉型為「AI 主線進攻者」。 過去市場將蘋果視為避險港灣,主因其擁有龐大現金流與極低的 AI 資本支出(Capex)負擔;但隨著 Apple Intelligence 深度嵌入 iOS 生態系,它正掌握著全球最龐大的 AI 終端變現入口。 1. 資本輕量化優勢: 當其他科技巨頭陷入算力燒錢大戰、市場質疑 ROI 時,蘋果以輕資產架構實現 AI 落地,具備極高的獲利防禦力。 2. 超級換機潮與訂閱變現: 22 億獲利裝置的龐大基底,將推動由 AI 主導的 iPhone 超級換機週期,同時帶動高毛利的 Services(服務)訂閱營收加速增長。 短線的防禦屬性為其提供了極高的安全邊際,而終端 AI 的商業化爆發,正是驅動股價重新領漲美股的核心進攻引擎!","text":"蘋果(AAPL):從防禦壁壘轉身,開啟 AI 主線進攻 蘋果完全有潛力從「防禦型現金牛」轉型為「AI 主線進攻者」。 過去市場將蘋果視為避險港灣,主因其擁有龐大現金流與極低的 AI 資本支出(Capex)負擔;但隨著 Apple Intelligence 深度嵌入 iOS 生態系,它正掌握著全球最龐大的 AI 終端變現入口。 1. 資本輕量化優勢: 當其他科技巨頭陷入算力燒錢大戰、市場質疑 ROI 時,蘋果以輕資產架構實現 AI 落地,具備極高的獲利防禦力。 2. 超級換機潮與訂閱變現: 22 億獲利裝置的龐大基底,將推動由 AI 主導的 iPhone 超級換機週期,同時帶動高毛利的 Services(服務)訂閱營收加速增長。 短線的防禦屬性為其提供了極高的安全邊際,而終端 AI 的商業化爆發,正是驅動股價重新領漲美股的核心進攻引擎!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/598995575214632","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":598632231063736,"gmtCreate":1787190369651,"gmtModify":1787190371513,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4246837204037102","idStr":"4246837204037102"},"themes":[],"title":"","htmlText":"Good ","listText":"Good ","text":"Good","images":[{"img":"https://community-static.tradeup.com/news/ddd66806c237858ebaef4b2dad8d73d7","width":"880","height":"1345"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/598632231063736","isVote":1,"tweetType":1,"viewCount":229,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":598624741004320,"gmtCreate":1787190271271,"gmtModify":1787190273079,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4246837204037102","idStr":"4246837204037102"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/598624741004320","isVote":1,"tweetType":1,"viewCount":194,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":598075580306400,"gmtCreate":1787041230806,"gmtModify":1787041232348,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4246837204037102","idStr":"4246837204037102"},"themes":[],"title":"","htmlText":"Good ","listText":"Good ","text":"Good","images":[{"img":"https://community-static.tradeup.com/news/b70ee719595c43cb7eecbb311138cce2","width":"880","height":"1149"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/598075580306400","isVote":1,"tweetType":1,"viewCount":314,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":598074426000600,"gmtCreate":1787040952731,"gmtModify":1787040955882,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4246837204037102","idStr":"4246837204037102"},"themes":[],"title":"","htmlText":"Good ","listText":"Good ","text":"Good","images":[{"img":"https://community-static.tradeup.com/news/96e45c24e58096d141195e0ca046c3a9","width":"880","height":"15206"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/598074426000600","isVote":1,"tweetType":1,"viewCount":217,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":597267625399080,"gmtCreate":1786843782443,"gmtModify":1786846142426,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4246837204037102","idStr":"4246837204037102"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/US91282CEC10.BOND\">$美國中期國債 1.875% 2027/02/28(US91282CEC10.BOND)$</a> ","listText":"<a href=\"https://ttm.financial/S/US91282CEC10.BOND\">$美國中期國債 1.875% 2027/02/28(US91282CEC10.BOND)$</a> ","text":"$美國中期國債 1.875% 2027/02/28(US91282CEC10.BOND)$","images":[{"img":"https://community-static.tradeup.com/news/0a9b705f67a3881e3bced4da0b35fdfe","width":"1074","height":"1644"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/597267625399080","isVote":1,"tweetType":1,"viewCount":355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":597263449036184,"gmtCreate":1786842963289,"gmtModify":1786846142260,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4246837204037102","idStr":"4246837204037102"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/00700\">$騰訊控股(00700)$ </a> ","listText":"<a href=\"https://ttm.financial/S/00700\">$騰訊控股(00700)$ </a> ","text":"$騰訊控股(00700)$","images":[{"img":"https://community-static.tradeup.com/news/72f3e2d8131eeb02e2b9594e7b36c8b6","width":"1320","height":"2643"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/597263449036184","isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":597262605178240,"gmtCreate":1786842756958,"gmtModify":1786846143474,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4246837204037102","idStr":"4246837204037102"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/01810\">$小米集團-W(01810)$ </a> ","listText":"<a href=\"https://ttm.financial/S/01810\">$小米集團-W(01810)$ </a> ","text":"$小米集團-W(01810)$","images":[{"img":"https://community-static.tradeup.com/news/9da460dc7829b2933ffc514d3c33c52e","width":"1320","height":"2913"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/597262605178240","isVote":1,"tweetType":1,"viewCount":401,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":597261157528056,"gmtCreate":1786842488277,"gmtModify":1786842567565,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4246837204037102","idStr":"4246837204037102"},"themes":[],"title":"","htmlText":"Good , win ","listText":"Good , win ","text":"Good , win","images":[{"img":"https://community-static.tradeup.com/news/1876d7fdfcdd3eeddba4832de4321741","width":"880","height":"12451"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/597261157528056","isVote":1,"tweetType":1,"viewCount":272,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":598075580306400,"gmtCreate":1787041230806,"gmtModify":1787041232348,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4246837204037102","authorIdStr":"4246837204037102"},"themes":[],"title":"","htmlText":"Good ","listText":"Good ","text":"Good","images":[{"img":"https://community-static.tradeup.com/news/b70ee719595c43cb7eecbb311138cce2","width":"880","height":"1149"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/598075580306400","isVote":1,"tweetType":1,"viewCount":314,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":598074426000600,"gmtCreate":1787040952731,"gmtModify":1787040955882,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4246837204037102","authorIdStr":"4246837204037102"},"themes":[],"title":"","htmlText":"Good ","listText":"Good ","text":"Good","images":[{"img":"https://community-static.tradeup.com/news/96e45c24e58096d141195e0ca046c3a9","width":"880","height":"15206"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/598074426000600","isVote":1,"tweetType":1,"viewCount":217,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":597267625399080,"gmtCreate":1786843782443,"gmtModify":1786846142426,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4246837204037102","authorIdStr":"4246837204037102"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/US91282CEC10.BOND\">$美國中期國債 1.875% 2027/02/28(US91282CEC10.BOND)$</a> ","listText":"<a href=\"https://ttm.financial/S/US91282CEC10.BOND\">$美國中期國債 1.875% 2027/02/28(US91282CEC10.BOND)$</a> ","text":"$美國中期國債 1.875% 2027/02/28(US91282CEC10.BOND)$","images":[{"img":"https://community-static.tradeup.com/news/0a9b705f67a3881e3bced4da0b35fdfe","width":"1074","height":"1644"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/597267625399080","isVote":1,"tweetType":1,"viewCount":355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":597263449036184,"gmtCreate":1786842963289,"gmtModify":1786846142260,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4246837204037102","authorIdStr":"4246837204037102"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/00700\">$騰訊控股(00700)$ </a> ","listText":"<a href=\"https://ttm.financial/S/00700\">$騰訊控股(00700)$ </a> ","text":"$騰訊控股(00700)$","images":[{"img":"https://community-static.tradeup.com/news/72f3e2d8131eeb02e2b9594e7b36c8b6","width":"1320","height":"2643"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/597263449036184","isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":597262605178240,"gmtCreate":1786842756958,"gmtModify":1786846143474,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4246837204037102","authorIdStr":"4246837204037102"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/01810\">$小米集團-W(01810)$ </a> ","listText":"<a href=\"https://ttm.financial/S/01810\">$小米集團-W(01810)$ </a> ","text":"$小米集團-W(01810)$","images":[{"img":"https://community-static.tradeup.com/news/9da460dc7829b2933ffc514d3c33c52e","width":"1320","height":"2913"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/597262605178240","isVote":1,"tweetType":1,"viewCount":401,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":597261157528056,"gmtCreate":1786842488277,"gmtModify":1786842567565,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4246837204037102","authorIdStr":"4246837204037102"},"themes":[],"title":"","htmlText":"Good , win ","listText":"Good , win ","text":"Good , win","images":[{"img":"https://community-static.tradeup.com/news/1876d7fdfcdd3eeddba4832de4321741","width":"880","height":"12451"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/597261157528056","isVote":1,"tweetType":1,"viewCount":272,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":600774612177672,"gmtCreate":1787710474396,"gmtModify":1787710477126,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4246837204037102","authorIdStr":"4246837204037102"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/600774612177672","isVote":1,"tweetType":1,"viewCount":25,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":600136286150960,"gmtCreate":1787559288758,"gmtModify":1787559291430,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4246837204037102","authorIdStr":"4246837204037102"},"themes":[],"title":"","htmlText":"Good ","listText":"Good ","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/600136286150960","repostId":"599535294231744","repostType":1,"repost":{"id":599535294231744,"gmtCreate":1787412576386,"gmtModify":1787559010531,"author":{"id":"4141520327734232","authorId":"4141520327734232","name":"慕容風股評","avatar":"https://community-static.tradeup.com/news/63610cfc631c9f4a6adb40c67a289ee2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4141520327734232","authorIdStr":"4141520327734232"},"themes":[],"title":"GLP-1RA能否提前進入糖尿病治療路徑?","htmlText":"過去治療2型糖尿病,常見做法是先控制飲食和運動,再使用二甲雙胍;血糖仍不達標,才逐級加入磺脲類、DPP-4抑制劑、SGLT2抑制劑或注射藥物,最後才考慮胰島素。這套模式成本較低、醫生經驗充足,卻容易把治療變成追逐糖化血紅蛋白數字:每次等待數月,待血糖失控才加藥,患者的體重、心血管及腎臟風險可能已持續累積。 GLP-1受體激動劑(GLP-1RA)的角色因而正在改變。問題已不是「是否比二甲雙胍更強」,而是哪一類患者若延後使用,可能錯過較佳的風險幹預窗口。 從逐級加藥走向風險分層 新版指南已不再要求所有患者依循同一條路徑。《中國糖尿病防治指南(2024版)》強調早期良好控制及合理聯合治療;對合併動脈粥樣硬化性心血管疾病或屬高危者,應選擇具有明確心血管獲益證據的GLP-1RA或SGLT2抑制劑;若患者超重或肥胖,用藥時亦應把減重效果列為重要考慮。美國糖尿病協會2026年標準更進一步,對已確診或高風險心血管疾病患者,建議使用具有結局證據的GLP-1RA,而不必等待糖化血紅蛋白失控,也不以是否已使用二甲雙胍為前提。 這不等於GLP-1RA應全面取代二甲雙胍。對沒有肥胖、心腎疾病而血糖升幅溫和的患者,二甲雙胍仍具價格低、經驗成熟及可及性高等優勢。若患者以心力衰竭或慢性腎病為主要風險,SGLT2抑制劑往往更具優先性;出現嚴重高血糖、酮症或明顯消瘦時,胰島素亦不能被延誤。 較適合提前使用GLP-1RA的,主要是肥胖、心血管高危、需要避免體重增加,或容易發生低血糖的患者。GLP-1RA以葡萄糖依賴方式促進胰島素分泌,單獨使用的低血糖風險較低,也避免部分磺脲類及胰島素帶來的體重增加。不過,胃腸道反應、注射接受程度、長期依從性及藥費,仍會令「指南推薦」與「真實使用」存在距離。 派達康要跨越的不只是獲批門檻 派格生物(02565.HK)的維培那肽注射液派達康,是觀察這場路徑轉變的合適案例。產品於20","listText":"過去治療2型糖尿病,常見做法是先控制飲食和運動,再使用二甲雙胍;血糖仍不達標,才逐級加入磺脲類、DPP-4抑制劑、SGLT2抑制劑或注射藥物,最後才考慮胰島素。這套模式成本較低、醫生經驗充足,卻容易把治療變成追逐糖化血紅蛋白數字:每次等待數月,待血糖失控才加藥,患者的體重、心血管及腎臟風險可能已持續累積。 GLP-1受體激動劑(GLP-1RA)的角色因而正在改變。問題已不是「是否比二甲雙胍更強」,而是哪一類患者若延後使用,可能錯過較佳的風險幹預窗口。 從逐級加藥走向風險分層 新版指南已不再要求所有患者依循同一條路徑。《中國糖尿病防治指南(2024版)》強調早期良好控制及合理聯合治療;對合併動脈粥樣硬化性心血管疾病或屬高危者,應選擇具有明確心血管獲益證據的GLP-1RA或SGLT2抑制劑;若患者超重或肥胖,用藥時亦應把減重效果列為重要考慮。美國糖尿病協會2026年標準更進一步,對已確診或高風險心血管疾病患者,建議使用具有結局證據的GLP-1RA,而不必等待糖化血紅蛋白失控,也不以是否已使用二甲雙胍為前提。 這不等於GLP-1RA應全面取代二甲雙胍。對沒有肥胖、心腎疾病而血糖升幅溫和的患者,二甲雙胍仍具價格低、經驗成熟及可及性高等優勢。若患者以心力衰竭或慢性腎病為主要風險,SGLT2抑制劑往往更具優先性;出現嚴重高血糖、酮症或明顯消瘦時,胰島素亦不能被延誤。 較適合提前使用GLP-1RA的,主要是肥胖、心血管高危、需要避免體重增加,或容易發生低血糖的患者。GLP-1RA以葡萄糖依賴方式促進胰島素分泌,單獨使用的低血糖風險較低,也避免部分磺脲類及胰島素帶來的體重增加。不過,胃腸道反應、注射接受程度、長期依從性及藥費,仍會令「指南推薦」與「真實使用」存在距離。 派達康要跨越的不只是獲批門檻 派格生物(02565.HK)的維培那肽注射液派達康,是觀察這場路徑轉變的合適案例。產品於20","text":"過去治療2型糖尿病,常見做法是先控制飲食和運動,再使用二甲雙胍;血糖仍不達標,才逐級加入磺脲類、DPP-4抑制劑、SGLT2抑制劑或注射藥物,最後才考慮胰島素。這套模式成本較低、醫生經驗充足,卻容易把治療變成追逐糖化血紅蛋白數字:每次等待數月,待血糖失控才加藥,患者的體重、心血管及腎臟風險可能已持續累積。 GLP-1受體激動劑(GLP-1RA)的角色因而正在改變。問題已不是「是否比二甲雙胍更強」,而是哪一類患者若延後使用,可能錯過較佳的風險幹預窗口。 從逐級加藥走向風險分層 新版指南已不再要求所有患者依循同一條路徑。《中國糖尿病防治指南(2024版)》強調早期良好控制及合理聯合治療;對合併動脈粥樣硬化性心血管疾病或屬高危者,應選擇具有明確心血管獲益證據的GLP-1RA或SGLT2抑制劑;若患者超重或肥胖,用藥時亦應把減重效果列為重要考慮。美國糖尿病協會2026年標準更進一步,對已確診或高風險心血管疾病患者,建議使用具有結局證據的GLP-1RA,而不必等待糖化血紅蛋白失控,也不以是否已使用二甲雙胍為前提。 這不等於GLP-1RA應全面取代二甲雙胍。對沒有肥胖、心腎疾病而血糖升幅溫和的患者,二甲雙胍仍具價格低、經驗成熟及可及性高等優勢。若患者以心力衰竭或慢性腎病為主要風險,SGLT2抑制劑往往更具優先性;出現嚴重高血糖、酮症或明顯消瘦時,胰島素亦不能被延誤。 較適合提前使用GLP-1RA的,主要是肥胖、心血管高危、需要避免體重增加,或容易發生低血糖的患者。GLP-1RA以葡萄糖依賴方式促進胰島素分泌,單獨使用的低血糖風險較低,也避免部分磺脲類及胰島素帶來的體重增加。不過,胃腸道反應、注射接受程度、長期依從性及藥費,仍會令「指南推薦」與「真實使用」存在距離。 派達康要跨越的不只是獲批門檻 派格生物(02565.HK)的維培那肽注射液派達康,是觀察這場路徑轉變的合適案例。產品於20","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/599535294231744","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":132,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":599739743027544,"gmtCreate":1787462480290,"gmtModify":1787462483006,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4246837204037102","authorIdStr":"4246837204037102"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/599739743027544","isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":599195005837520,"gmtCreate":1787329570577,"gmtModify":1787329572002,"author":{"id":"4246837204037102","authorId":"4246837204037102","name":"wslam","avatar":"https://community-static.tradeup.com/news/a078bf920a5829ac40bb5fc9e7516cbb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4246837204037102","authorIdStr":"4246837204037102"},"themes":[],"title":"","htmlText":"Good ","listText":"Good ","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/599195005837520","repostId":"599035632738552","repostType":1,"repost":{"id":599035632738552,"gmtCreate":1787290664620,"gmtModify":1787321248345,"author":{"id":"4242190439147992","authorId":"4242190439147992","name":"段飛特","avatar":"https://community-static.tradeup.com/news/58c5dd517a3243d939006f06d2f74890","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4242190439147992","authorIdStr":"4242190439147992"},"themes":[],"title":"","htmlText":"需求已經達到產能的150%,還在擔心科技見頂? 1、長債收益率一日遊,債券壓力依然存在昨晚 <a href=\"https://ttm.financial/S/US30Y.BOND\">$美國30年期國債收益率(US30Y.BOND)$ </a> 重新收復週三貝森特出手的影響,此前打下去的收益率基本又漲回來了 只要你的財政紀律沒有實質性的約束,你的債務規模就是會不斷擴張的 美債的風險問題從零幾年的時候就開始討論了,現在已經20年過去了,哪屆ZF真的解決過這個問題?就算你想解決,你敢加稅嗎?你的選民答應嗎? 另外科技股的資本支出毫無放緩的意向,雖然長債收益率在攀升,但是並不影響他們的發債節奏,這點貝森特說的倒是真的,科技公司對債券利率真的沒那麼敏感 關於長債的收益率,昨晚貝森特還是再次強調了一下,戶部有強大的工具箱,下個月開始的國債收購規模可能超過40億美元的上限 但是光靠回購也只能影響短期走向,改變不了趨勢,要想長債收益率降低,我覺得指望財政紀律約束是有點難了,不如指望通脹降溫,聯儲局繼續減息吧 如果接下來通脹能夠降溫,長債收益率降低的話,對科技股來說就是宏觀順風,如果長債收益率持續快速的走高,對科技股來說終究是壓製作用 2、真的該重新審視存儲的邏輯了 昨天的文章講,這波長債收益率對科技股的衝擊其實是次要因素,是個導火索,其調整的核心邏輯還是反彈見頂,市場需要時間繼續盤整消化 從這兩天的盤面看市場主要也是內部切換,硬件和軟件蹺蹺板效應,並非邏輯破裂的崩潰式走勢 所以要想把握科技股的長期走勢,還是要看科技股自身的基本面情況,這裏不得不再次強調一下存儲板塊 很多人還是擔憂存儲是不是還是週期股,這波漲價見頂之後股價就要大幅回落了? 其實不然,之前已經多次和大家解讀過,這波存儲的週期屬性已經被大幅減弱了,即使不敢完全把它當成成長股來看,也要對這波週期上行","listText":"需求已經達到產能的150%,還在擔心科技見頂? 1、長債收益率一日遊,債券壓力依然存在昨晚 <a href=\"https://ttm.financial/S/US30Y.BOND\">$美國30年期國債收益率(US30Y.BOND)$ </a> 重新收復週三貝森特出手的影響,此前打下去的收益率基本又漲回來了 只要你的財政紀律沒有實質性的約束,你的債務規模就是會不斷擴張的 美債的風險問題從零幾年的時候就開始討論了,現在已經20年過去了,哪屆ZF真的解決過這個問題?就算你想解決,你敢加稅嗎?你的選民答應嗎? 另外科技股的資本支出毫無放緩的意向,雖然長債收益率在攀升,但是並不影響他們的發債節奏,這點貝森特說的倒是真的,科技公司對債券利率真的沒那麼敏感 關於長債的收益率,昨晚貝森特還是再次強調了一下,戶部有強大的工具箱,下個月開始的國債收購規模可能超過40億美元的上限 但是光靠回購也只能影響短期走向,改變不了趨勢,要想長債收益率降低,我覺得指望財政紀律約束是有點難了,不如指望通脹降溫,聯儲局繼續減息吧 如果接下來通脹能夠降溫,長債收益率降低的話,對科技股來說就是宏觀順風,如果長債收益率持續快速的走高,對科技股來說終究是壓製作用 2、真的該重新審視存儲的邏輯了 昨天的文章講,這波長債收益率對科技股的衝擊其實是次要因素,是個導火索,其調整的核心邏輯還是反彈見頂,市場需要時間繼續盤整消化 從這兩天的盤面看市場主要也是內部切換,硬件和軟件蹺蹺板效應,並非邏輯破裂的崩潰式走勢 所以要想把握科技股的長期走勢,還是要看科技股自身的基本面情況,這裏不得不再次強調一下存儲板塊 很多人還是擔憂存儲是不是還是週期股,這波漲價見頂之後股價就要大幅回落了? 其實不然,之前已經多次和大家解讀過,這波存儲的週期屬性已經被大幅減弱了,即使不敢完全把它當成成長股來看,也要對這波週期上行","text":"需求已經達到產能的150%,還在擔心科技見頂? 1、長債收益率一日遊,債券壓力依然存在昨晚 $美國30年期國債收益率(US30Y.BOND)$ 重新收復週三貝森特出手的影響,此前打下去的收益率基本又漲回來了 只要你的財政紀律沒有實質性的約束,你的債務規模就是會不斷擴張的 美債的風險問題從零幾年的時候就開始討論了,現在已經20年過去了,哪屆ZF真的解決過這個問題?就算你想解決,你敢加稅嗎?你的選民答應嗎? 另外科技股的資本支出毫無放緩的意向,雖然長債收益率在攀升,但是並不影響他們的發債節奏,這點貝森特說的倒是真的,科技公司對債券利率真的沒那麼敏感 關於長債的收益率,昨晚貝森特還是再次強調了一下,戶部有強大的工具箱,下個月開始的國債收購規模可能超過40億美元的上限 但是光靠回購也只能影響短期走向,改變不了趨勢,要想長債收益率降低,我覺得指望財政紀律約束是有點難了,不如指望通脹降溫,聯儲局繼續減息吧 如果接下來通脹能夠降溫,長債收益率降低的話,對科技股來說就是宏觀順風,如果長債收益率持續快速的走高,對科技股來說終究是壓製作用 2、真的該重新審視存儲的邏輯了 昨天的文章講,這波長債收益率對科技股的衝擊其實是次要因素,是個導火索,其調整的核心邏輯還是反彈見頂,市場需要時間繼續盤整消化 從這兩天的盤面看市場主要也是內部切換,硬件和軟件蹺蹺板效應,並非邏輯破裂的崩潰式走勢 所以要想把握科技股的長期走勢,還是要看科技股自身的基本面情況,這裏不得不再次強調一下存儲板塊 很多人還是擔憂存儲是不是還是週期股,這波漲價見頂之後股價就要大幅回落了? 其實不然,之前已經多次和大家解讀過,這波存儲的週期屬性已經被大幅減弱了,即使不敢完全把它當成成長股來看,也要對這波週期上行","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/599035632738552","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":185,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}